You need to enable JavaScript to run this app.
Analyses reveal wide variation in PRO measures in cancer trials
Regulatory News
Mary Ellen Schneider
Clinical Trials
North America
Pharmaceuticals
Regulatory NewsMary Ellen Schneider
Clinical TrialsNorth AmericaPharmaceuticalsRegulatory NewsMary Ellen SchneiderClinical TrialsNorth AmericaPharmaceuticals